← All indications
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Subtype terms (7)
More specific conditions that are subtypes of Leukemia, Myeloid in the MeSH hierarchy.
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
260 drugs (137 approved, 123 experimental)
- Leukemia, Myeloid, Acute
1048 drugs (293 approved, 755 experimental)
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
134 drugs (105 approved, 29 experimental)
- Leukemia, Myelomonocytic, Acute
70 drugs (47 approved, 23 experimental)
- Leukemia, Myelomonocytic, Chronic
237 drugs (130 approved, 107 experimental)
- Leukemia, Myelomonocytic, Juvenile
61 drugs (45 approved, 16 experimental)
- Sarcoma, Myeloid
40 drugs (32 approved, 8 experimental)
Drugs by status
Approved for this indication (4)
Phase 3 trials (31)
- cladribine
- azacitidine
- mercaptopurine
- sorafenib
- imatinib
- naltrexone
- idarubicin
- bc8
- caspofungin
- radotinib
- allogeneic hematopoietic stem cells
- platelets
- arsenic trioxide
- cyclosporine
- mycophenolate
- cyclophosphamide
- daunorubicin
- allogeneic lymphocytes
- fluconazole
- Anti-thymocyte Globulin (Rabbit)
- bortezomib
- fludarabine
- enasidenib
- etoposide
- cytarabine
- chlorhexidine
- asparaginase
- tretinoin
- mitoxantrone
- nilotinib
- +1 more
Phase 2 trials (35)
- allopurinol
- decitabine
- allogeneic natural killer cells
- as1411
- venetoclax
- lenalidomide
- cc-90011
- clofarabine
- tacrolimus
- hemopoietic stem cell
- aldesleukin
- hydrocortisone
- imtox-25
- Filgrastim
- nivolumab
- lestaurtinib
- vitamin c
- pevonedistat
- sirolimus
- temozolomide
- dasatinib
- futibatinib
- nicotinamide
- zosuquidar
- cytokine induced killer cells
- methotrexate
- thiotepa
- sargramostim
- melphalan
- momelotinib
- +5 more
Phase 1 trials (31)
- barasertib
- cc-401
- mk-0752
- imc-eb10
- Imetelstat
- hyaluronidase (human recombinant)
- leucovorin
- mbg453
- pexidartinib
- posaconazole
- ruxolitinib
- multi-peptide cmv-modified vaccinia ankara vaccine
- oxygen
- ivosidenib
- daratumumab
- amg-900
- ave-9633
- prednisolone
- interferon gamma-1b
- letermovir
- spartalizumab
- imgn632
- ciml nk
- Olverembatinib
- ziftomenib
- cynk-001
- ft538
- cc-96191
- hs-10382
- bh-30236
- +1 more
Organizations
Organization Involved with Phase 4 Indications (49)
- Fujian Medical University
- Inje University
- Developmental Therapeutics Consortium
- Postgraduate Institute of Medical Education and Research
- Novartis
- Bristol-Myers Squibb
- Pfizer
- Meda
- University of Valencia
- Peking University
- EpiCept Corporation
- Universidad Autonoma de Nuevo Leon
- China Medical University
- PETHEMA Foundation
- Sun Yat-Sen University
- Medical College of Wisconsin
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Universidad Autonoma de Barcelona
- Gachon University
- Merck
- University of Texas at Houston
- Guangzhou Medical University
- Soochow University
- Cornell University
- Soonchunhyang University
- Korea University
- Technical University of Dresden
- Russian Academy of Medical Sciences
- University of Barcelona
- Universidad Complutense de Madrid
- +19 more
Organization Involved with Phase 3 Indications (202)
- Copernicus Memorial Hospital
- Clinipace LTD
- University of Munster
- University of Adelaide
- Boehringer Ingelheim
- Shandong University
- Belgian Hematological Society
- Cardiff University
- Cyclacel Pharmaceuticals, Inc.
- University of Bologna
- Celgene
- Cairo University
- Northwell Health
- Eisai
- University of Texas, San Antonio
- Dutch Childhood Oncology Group
- Delta-Fly Pharma, Inc.
- Northwestern University
- French Innovative Leukemia Organisation
- National Heart, Lung, and Blood Institute (NHLBI)
- Erasmus University Rotterdam
- University of Chicago
- University of Birmingham
- Kaiser Permanente
- People's Liberation Army of China
- University of Rome Tor Vergata
- Royal Liverpool & Broadgreen University Hospitals NHS Truts
- University of Leipzig
- People's Hospital of Rizhao
- Eastern Cooperative Oncology Group
- +172 more
Organization Involved with Phase 2 Indications (358)
- Chung-Ang University
- Lund University
- Hospital Santa Marcelina, Sao Paulo, Brasil
- Karolinska Institute
- University of Rochester
- OHSU Knight Cancer Institute
- Hopital Rene Huguenin_Intitut Curie_Paris
- Forma Therapeutics, Inc.
- Department of Veteran Affairs
- Syntax for Science
- Chu De Liège
- Theradex
- Telios Pharma, Inc.
- OCT Clinical Trials
- Vanderbilt University
- University of Tuebingen
- Ospedale Sant' Eugenio
- The Korean Society of Hematology
- Cellerant Therapeutics
- SGX Pharmaceuticals
- University of Kentucky
- ICON
- Cure CML Consortium
- Selvita S.A.
- Shanghai institute of Hematology
- Pennsylvania State University
- Yale University
- University of Bern
- Mario Negri Institute
- Otsuka
- +328 more
Organization Involved with Phase 1 Indications (125)
- Threshold Pharmaceuticals
- Kyowa Kirin
- University of Utah
- Proswell Medical Corporation
- Georgia Institute of Technology
- BioTheryX, Inc.
- Jinan University
- William Marsh Rice University
- CStone Pharmaceuticals
- Texas Tech University
- Constant Pharmaceuticals
- Hebei Senlang Biotechnology Inc., Ltd.
- Celyad
- LAM Therapeutics Inc.
- Ozmosis Research Inc.
- Damon Runyon Cancer Research Foundation
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Melbourne Health
- Zenith Epigenetics
- University of Science and Technology of China
- Elimination of Leukaemia Fund
- Parexel
- Immune-Onc Therapeutics Inc
- Yake Biotechnology Ltd.
- GEMoaB Monoclonals GmbH
- Aileron Therapeutics
- Wuhan Bio-Raid Biotechnology Co, Ltd. China
- In8Bio
- Institut de Recherche Clinique sur les Cancers et le Sang
- Sunshine Lake Pharma Co., Ltd.
- +95 more
Organization Involved with Other Experimental Indications (17)
- King Faisal Specialist Hospital
- Aix-University of Marseille
- Eligix
- King Faisal University
- Medical University of Vienna
- Swiss National Science Foundation
- University of Sao Paulo
- American University of Beirut
- MacroGenics
- Immunex
- Integrated Community Oncology Network
- Shengjing Hospital
- West Virginia University
- National Institute on Aging (NIA)
- ESP Pharma
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
- Linkoping University